Alpha Fetoprotein, CSF (Tumor Marker)
Also known as: AFP CSF
Use
Alpha Fetoprotein (AFP) is a valuable aid in the management of nonseminomatous testicular cancer patients when used in conjunction with clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in conditions such as ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with or without liver metastases, and in benign hepatic conditions like acute viral hepatitis, chronic active hepatitis, and cirrhosis.
Special Instructions
This test uses the Beckman Coulter Access DxI AFP method. Results obtained with different assay methods or kits cannot be used interchangeably. It is important to note that the test result cannot be interpreted as absolute evidence of the presence or absence of malignant disease and is not interpretable as a tumor marker in pregnant females.
Limitations
The test may not provide absolute evidence of malignant disease presence or absence. Its results cannot be interchangeable with other assay methods, and it is not interpretable as a tumor marker for pregnant females.
New York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 1833-3
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated.
Causes for Rejection
Any specimens other than CSF.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |